Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.64 |
| ▸ | ECE1 | P42892 | 8/20 | 0.62 |
| ▸ | CTSC | P53634 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.57 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429294 | 0.92 | ACE (0.66) | ACEECE1OPRM1OPRD1ALOX15 | |
| SCHEMBL9870210 | 0.92 | ACE (0.66) | ACEECE1OPRM1OPRD1ALOX15 | |
| SCHEMBL30051300 | 0.91 | ACE (0.60) | ACEECE1OPRM1OPRD1ALOX15 | |
| Valyltryptophan SCHEMBL150533 | 0.89 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| Valyltryptophan SCHEMBL30821897 | 0.89 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| Valyltryptophan SCHEMBL150532 | 0.89 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| Valyltryptophan SCHEMBL29365770 | 0.89 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| Valyltryptophan SCHEMBL30821963 | 0.89 | ACE (0.75) | ACEECE1CTSCALOX15 | |
| SCHEMBL30052764 | 0.89 | KDM4E (0.62) | ACEECE1OPRM1OPRD1ALOX15 | |
| SCHEMBL30051470 | 0.88 | ECE1 (0.66) | ACEECE1OPRM1OPRD1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885ECE1 1629/4885CTSC 131/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ACE 486/4885ECE1 997/4885CTSC 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.